Skip to main content

Table 4 Growth inhibition of combination treatment in TP53 Mut cell lines

From: MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines

Mean IC50 ± SE(nM)

 

Doxorubicin

Cisplatin

Methotrexate

 

alone

combination

alone

combination

alone

combination

RMS13

14 ± 4

6 ± 3

855 ± 143

244 ± 85

106 ± 34

253 ± 75

SaOS-2

77 ± 12

40 ± 17

4828 ± 4855

517 ± 229

636 ± 806

na

  1. RMS13 and SaOS-2 cells were exposed to a concentration range of Nutlin-3a, Doxorubicin, Cisplatin, Methotrexate and combinations for 120 h. Values (IC50 in nM) are means ± standard error of the mean (SE) for 3-5 experiments. The decrease observed in the combination of Nutlin-3a with Doxorubicin or Cisplatin, indicates that Nutlin-3a potentiates Doxorubicin and Cisplatin, whereas the increase in IC50 observed for the combination with Methotrexate indicates that Nutlin-3a inhibits Methotrexate.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us